NCT06635772View on ClinicalTrials.gov

A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

April 30, 2026

Conditions

Immunoglobulin a Nephropathy

Interventions

DRUG

HS-10390

HS-10390 will be administered daily

DRUG

Irbesartan

Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06635772 - A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy | Biotech Hunter | Biotech Hunter